Cargando…

Profiling Prostate Cancer Therapeutic Resistance

The major challenge in the treatment of patients with advanced lethal prostate cancer is therapeutic resistance to androgen-deprivation therapy (ADT) and chemotherapy. Overriding this resistance requires understanding of the driving mechanisms of the tumor microenvironment, not just the androgen rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wade, Cameron A., Kyprianou, Natasha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877765/ https://www.ncbi.nlm.nih.gov/pubmed/29562686 http://dx.doi.org/10.3390/ijms19030904

Ejemplares similares

Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance
por: Archer, Maddison, et al.
Publicado: (2020)

Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
por: Kahn, Barbara, et al.
Publicado: (2014)

Inflammation in prostate cancer progression and therapeutic targeting
por: Stark, Timothy, et al.
Publicado: (2015)

Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance
por: Altschuler, Joshua, et al.
Publicado: (2021)

Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer
por: Gaglani, Simita, et al.
Publicado: (2021)

Mechanisms navigating the TGF-β pathway in prostate cancer
por: Cao, Zheng, et al.
Publicado: (2015)

Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer
por: Kyprianou, Natasha, et al.
Publicado: (2021)

Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression
por: Grant, Campbell M., et al.
Publicado: (2013)

Prostate tumor neuroendocrine differentiation via EMT: The road less traveled
por: Dicken, Haley, et al.
Publicado: (2019)

Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer
por: Chakraborty, Goutam, et al.
Publicado: (2023)

Circadian Rhythm Disruption as a Contributor to Racial Disparities in Prostate Cancer
por: Dasari, Sonali S., et al.
Publicado: (2022)

A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review)
por: LACY, JOHN M., et al.
Publicado: (2014)

Anoikis in phenotypic reprogramming of the prostate tumor microenvironment
por: Nepali, Prerna R., et al.
Publicado: (2023)

The Promise of Novel Molecular Markers in Bladder Cancer
por: Miremami, Jahan, et al.
Publicado: (2014)

Emerging biomarkers of prostate cancer (Review)
por: MARTIN, SARAH K., et al.
Publicado: (2012)

Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer
por: Chen, Tzu-Yi, et al.
Publicado: (2023)

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
por: Bumbaca, Brandon, et al.
Publicado: (2018)

New Therapeutics to Treat Castrate-Resistant Prostate Cancer
por: Acar, Ömer, et al.
Publicado: (2013)

Molecular Signatures in Urologic Tumors
por: Larkin, Spencer, et al.
Publicado: (2013)

Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells
por: Cao, Zheng, et al.
Publicado: (2017)

Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists
por: Dovey, Zachary, et al.
Publicado: (2020)

Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance
por: Lima, Thiago S., et al.
Publicado: (2021)

Novel Pharmacologic Targeting of Tight Junctions and Focal Adhesions in Prostate Cancer Cells
por: Hensley, Patrick J., et al.
Publicado: (2014)

Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer
por: Chakravarty, Dimple, et al.
Publicado: (2020)

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer
por: Schaaf, Zachary A., et al.
Publicado: (2023)

Homeless Cells Escape Death and Deliver Lethal Cancer
por: Archer, Maddison, et al.
Publicado: (2021)

Prostate cancer and therapeutic challenges
por: Hawsawi, Yousef MohammedRabaa, et al.
Publicado: (2020)

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
por: Greasley, Rosa, et al.
Publicado: (2015)

Cancer-Associated Fibroblast: Role in Prostate Cancer Progression to Metastatic Disease and Therapeutic Resistance
por: Bedeschi, Martina, et al.
Publicado: (2023)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance
por: Saldana, Carolina, et al.
Publicado: (2021)

Novel non-AR therapeutic targets in castrate resistant prostate cancer
por: Toren, Paul J., et al.
Publicado: (2013)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
por: Sartor, A Oliver
Publicado: (2011)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
por: Kase, Adam M, et al.
Publicado: (2020)

COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer
por: Mihalopoulos, Meredith, et al.
Publicado: (2020)

Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis
por: Harris, Koran S., et al.
Publicado: (2017)

Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance
por: Ge, Rongbin, et al.
Publicado: (2022)

Hedgehog Signaling in Prostate Development, Regeneration and Cancer
por: Bushman, Wade
Publicado: (2016)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sbj1ubvcmmqvpe9di6840liv5a